Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005 in Huntington’s Disease Following…

Posted: January 5, 2022 at 2:30 am

ANX005 Has Been Generally Well-Tolerated and Has Shown Full Target Engagement of C1q in the CSF

Originally posted here:
Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005 in Huntington’s Disease Following...

Related Posts